arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Vanda Pharmaceuticals Inc.

VNDA
$5.12 ▲ +0.46 (+9.76%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

Vanda Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $301.7M
Dividend Yield
Revenue Growth 8.7%
Op. Margin -70.0%
ROIC -73.5%
FCF / Share $-1.87
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$216.10M
↑ +8.7%
Net Income Profit after all expenses
$-220.47M
↓ -1066.5%
Operating Margin Operating profit as % of sales
-70.0%
↓ -242.0% 4th
FCF / Share Free cash flow per share
$-1.87
↓ -570.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
13
Cash Quality
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters